Growth Metrics

Gyre Therapeutics (GYRE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $649000.0.

  • Gyre Therapeutics' Depreciation & Amortization (CF) rose 4584.27% to $649000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 6493.51%. This contributed to the annual value of $1.5 million for FY2024, which is 4422.72% up from last year.
  • Per Gyre Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $649000.0 for Q3 2025, which was up 4584.27% from $641000.0 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $867000.0 for Q4 2022, and its period low was $40000.0 during Q3 2022.
  • In the last 5 years, Gyre Therapeutics' Depreciation & Amortization (CF) had a median value of $276000.0 in 2023 and averaged $306578.9.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 65391.3% in 2022, then plummeted by 6562.86% in 2023.
  • Over the past 5 years, Gyre Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $115000.0 in 2021, then soared by 653.91% to $867000.0 in 2022, then crashed by 65.63% to $298000.0 in 2023, then skyrocketed by 54.7% to $461000.0 in 2024, then skyrocketed by 40.78% to $649000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $649000.0 for Q3 2025, versus $641000.0 for Q2 2025 and $535000.0 for Q1 2025.